SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE). Background: On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In a ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Pfizer Inc. (NYSE: PFE ) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR ...

Group 1 - Pfizer Inc (NYSE:PFE) stock increased by 2.6% to $24.65 following the announcement of its acquisition of weight-loss drug company Metsera (MTSR) for up to $7.3 billion [1] - The stock is experiencing its best single-day percentage gain since July and has gained in three of the last four sessions, although it faces resistance at the $25 level after a pullback in late August [1] - Over the past 12 months, PFE's stock has decreased by 16.5% [1] Group 2 - Options trading activity for PFE has surged, with 115,000 calls traded, which is four times the average intraday volume, compared to only 17,000 puts [2] - New positions are being opened at the most active contracts, specifically the October 25 and 9/26 24.50 calls [2] Group 3 - The 50-day call/put volume ratio for PFE is 2.72, indicating that options traders are significantly more bullish than usual, ranking higher than 82% of readings from the past year [3] - The Schaeffer's Volatility Index (SVI) for PFE is at 23%, placing it in the 5th percentile of its annual range, suggesting that options traders are anticipating low volatility [4]

Core Insights - Pfizer Inc. is acquiring obesity startup Metsera Inc. for $4.9 billion to enhance its position in the competitive obesity market after struggling with its own weight-loss medications [1][2][7] - The acquisition includes an initial payment of $47.50 per share, with potential additional payments bringing the total deal value to $7.3 billion, representing a 43% premium over Metsera's recent closing price [1][6] Company Strategy - Pfizer is focusing on rebuilding its portfolio post-pandemic, as demand for its COVID-related products declines and key drugs approach patent expiration [2][7] - The company aims to leverage Metsera's pipeline of experimental weight-loss drugs to compete with established players like Eli Lilly and Novo Nordisk [6][10] Market Context - The obesity market is projected to reach $100 billion by 2030, attracting interest from various pharmaceutical companies [6] - Metsera is developing long-acting amylin analogues, which may offer a gentler alternative to existing GLP-1 drugs, potentially positioning Pfizer favorably in the obesity treatment landscape [8][10] Financial Implications - Pfizer's acquisition strategy includes a commitment to spend up to $15 billion on acquisitions by 2025, indicating a proactive approach to pipeline replenishment [11] - The company has faced significant stock price declines, approximately 60% from its pandemic peak, highlighting the urgency for new growth avenues [7]

Group 1 - Pfizer announced the acquisition of Metsera for $4.9 billion upfront, with potential milestone payments of approximately $2.4 billion, bringing the total valuation to $7.3 billion, expected to close in Q4 2025 [1][2] - The acquisition led to a significant drop in the stock prices of two Chinese weight-loss drug concept stocks, with Borui Pharmaceutical down 13.15% and Zhongsheng Pharmaceutical down 6.28%, as the market speculated the loss of a potential buyer like Pfizer [1] - Metsera's lead drug, MET-097i, is a long-acting GLP-1 receptor agonist currently in Phase II clinical trials, and the company has two oral GLP-1 RA candidates nearing clinical trials [2][3] Group 2 - Pfizer's CEO Albert Bourla stated that the acquisition aligns with the company's strategy to focus on impactful investment areas, aiming to address unmet medical needs in obesity and related diseases [3] - The trend in drug development is shifting towards long-acting, multi-target, and oral medications, as evidenced by the challenges faced by Pfizer's previous GLP-1 drug candidates due to liver damage [2][3] - The global demand for GLP-1 drugs is driven by their significant weight-loss effects, making them highly sought after in the market [2]

Federal Reserve and Economic Indicators - Stephen Miran, the new Fed governor, will speak in New York, with Fed Chair Jerome Powell following on Tuesday, as markets await key inflation data on Friday [1][12] - A weak Personal Consumption Expenditures (PCE) report could increase the likelihood of another quarter-point rate cut in October, with Wall Street expecting September's PCE to show soft inflation [2][12] Gold and Cryptocurrency Market - Gold prices reached an all-time high of $3,750, driven by expectations of further Fed rate cuts before the end of 2025, while Bitcoin and other cryptocurrencies experienced significant declines, resulting in over $1.5 billion in losses for traders [3][11][12] Oracle Corporation Developments - Oracle's stock fell over 1% following the announcement of CEO Safra Catz's resignation, with the company appointing two new co-CEOs, Clay Magouyrk and Mike Sicilia, as part of a succession plan [5][13] - Earlier, Oracle shares rose due to news that the company will manage TikTok's algorithm in the US and store American user data, which is expected to positively impact Oracle's revenue from TikTok [7][13] Pfizer Acquisition - Pfizer announced its acquisition of Metsera, a weight-loss drug company, for $7.3 billion, with Metsera's stock soaring over 60% in premarket trading following the news [8][13] - Under the agreement, Pfizer will pay $47.50 per share for Metsera, valuing the company at $4.9 billion, with potential additional payments based on clinical and regulatory milestones [9][13] Market Sentiment and Upcoming Reports - Investors are closely monitoring Micron Technology's earnings report for insights into AI chip demand and Costco's results for consumer spending trends, alongside the University of Michigan's consumer sentiment index due Friday [10][13]

Core Viewpoint - Metsera, a startup focused on obesity drug development, saw its stock surge over 60% to a record high of $53.47 following Pfizer's agreement to acquire the company for approximately $4.9 billion, enhancing its research pipeline [1] Group 1: Acquisition Details - Pfizer will acquire Metsera for $47.50 per share in cash, with potential additional payments of up to $22.50 per share contingent on achieving three specific regulatory milestones [1] - The acquisition price represents a 43% premium over Metsera's closing price last Friday [1]

智通财经APP获悉，周一，肥胖症药物研发初创公司Metsera(MTSR.US)开盘暴涨超60%，创历史新高， 报53.47美元。消息面上，辉瑞(PFE.US)同意以约49亿美元的企业价值收购Metsera，此举旨在强化其研 发管线。这家美国制药商在周一的声明中表示，将以每股47.50美元的现金收购Metsera，若达成三项特 定监管里程碑，还将额外支付每股最高22.50美元。该交易较Metsera上周五收盘价溢价43%。 ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Core Viewpoint - U.S. stock market opened lower with the Dow Jones down 0.38%, Nasdaq down 0.12%, and S&P 500 down 0.22% [1] Group 1: Blockchain Sector - Some blockchain-related stocks experienced declines, with Circle down 3.2%, Strategy down 2.2%, and Coinbase down 2.5% [1] Group 2: Gold Market - Spot gold reached a new historical high, leading to a rise in gold stocks, with Harmony Gold up approximately 4% and Coeur Mining up around 3% [1] Group 3: Pharmaceutical Sector - Metsera, a developer of anti-obesity drugs, surged over 57% following reports that Pfizer is close to acquiring the company for $7.3 billion [1] - ASML shares rose over 3% after Morgan Stanley significantly raised its target price from €600 to €950 [1]